RxDoctor Payments Data

Stephanie Ladson Wofford, MD

Nephrology · Westerville, OHNPI 1689673329

Payments from drug & device makers

$1,760in general payments, 2019–2025

Across 102 payments — averaging $17.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$643
  • Bayer$187
  • Amgen$159
  • GSK$144
  • Otsuka America Pharmaceutical, Inc.$119
  • Novo Nordisk$87
  • plus $421 from 10 others

What the payments were for

  • Food & beverage$1,66795%
  • Education$935%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,760 in reported general payments places this provider in the 55th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$132,616
Medicare patients
255
Services billed
936

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol134$120,482
EliquisApixaban26$27,693
Sevelamer Carbonate47$20,337
JanuviaSitagliptin Phosphate15$18,389
JardianceEmpagliflozin17$17,028
ClinolipidFat Emulsion/Olive/Soy/Phospho47$15,624
Calcitriol586$12,645
Cinacalcet Hcl38$8,340
Midodrine Hcl13$7,076
Calcium Acetate33$4,683
Nifedipine ErNifedipine87$3,096
Pregabalin11$1,876
Losartan Potassium238$1,864
Potassium Chloride111$1,845
Amlodipine Besylate332$1,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$643$120,482134 claims
Boehringer IngelheimJardiance$19$17,02817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 450 nephrology providers in Ohio.

Other nephrology in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →